Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER2 testing recommendations in Australia.

M Bilous1,

  • 1Tissue Pathology Department, ICPMR, Westmead Hospital, NSW, Australia. michaelb@icpmr.wsahs.nsw.gov.au

Pathology
|February 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer.

Scientific reports·2019
Same author

Universal screening to identify gestational diabetes: a multi-centre study in the North of England.

Diabetes research and clinical practice·2013
Same author

A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.

Journal of clinical pathology·2008
Same author

Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3).

British journal of cancer·2007
Same author

A risk index for early node-negative breast cancer.

The British journal of surgery·2006
Same author

Is centralized histopathology review necessary for screen-detected breast lesions?

Breast (Edinburgh, Scotland)·2004

Trastuzumab (Herceptin) targets HER2-positive metastatic breast cancer. Accurate HER2 detection is crucial for patient selection, as only 20% of breast cancers overexpress this receptor. Current testing methods include immunohistochemistry and fluorescence in situ hybridization.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Diagnostics

Background:

  • Metastatic breast cancer treatment has advanced with targeted therapies.
  • Humanized monoclonal antibody trastuzumab (Herceptin) targets the HER2 receptor.
  • HER2 overexpression is present in approximately 20% of breast cancers, necessitating precise patient identification.

Purpose of the Study:

  • To highlight the importance of patient selection for HER2-targeted therapy.
  • To discuss the role of HER2 detection in eligibility for trastuzumab treatment.
  • To review current diagnostic methods for HER2 detection.

Main Methods:

  • Review of diagnostic techniques for HER2 detection.
  • Analysis of patient selection criteria for trastuzumab therapy.

Related Experiment Videos

  • Consideration of national and international testing recommendations.

    • Main Results:

    • Trastuzumab efficacy is linked to HER2 receptor status.
    • Accurate HER2 testing is paramount for identifying eligible patients.
    • Immunohistochemistry and fluorescence in situ hybridization are established HER2 detection methods.

    Conclusions:

    • Effective use of trastuzumab in metastatic breast cancer relies on accurate HER2 detection.
    • Patient selection based on HER2 status is critical for treatment success.
    • Established testing protocols guide HER2 detection and patient eligibility.